FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Fentanyl (Duragesic 100, 12, 25, 37, 50, 75) Extended-Release Film
Status: Discontinuation
»Therapeutic Categories: Analgesia/Addiction

Expand all

Janssen Pharmaceuticals (New 04/01/2020)

Company Contact Information:
800-526-7736

Presentation Posting Date Related Information
100 ug/1 h (NDC 50458-094-05) 04/01/2020 The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.
75 ug/1 h (NDC 50458-093-05) 04/01/2020 The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.
50 ug/1 h (NDC 50458-092-05) 04/01/2020 The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.
25 ug/1 h (NDC 50458-091-05) 04/01/2020 The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.
100 ug/1 unit (NDC 50458-106-05) 04/01/2020 The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.
75 ug/1 unit (NDC 50458-105-05) 04/01/2020 The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.
50 ug/1 unit (NDC 50458-104-05) 04/01/2020 The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.
25 ug/1 unit (NDC 50458-102-05) 04/01/2020 The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.
12.5 ug/1 unit (NDC 50458-101-05) 04/01/2020 The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.
12.5 ug/1 h (NDC 50458-090-05) 04/01/2020 The Company has made a business decision to permanently discontinue all Duragesic/fentanyl transdermal system. Product should be maintained on the formularies until the last batch produced expires (31 July 2021), in order to maintain continuity of the reimbursement process.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English